Iron infusion and MRI to study inflammation in HFpEF
Official title: Omega-3 Fatty Acids and Myocardial Inflammation in HFpEF: Preliminary Data and Next Steps
Run by University of Florida · NCT07634640 · Data updated 2026-11-12
A small early-phase study tests whether an iron infusion affects heart inflammation in people with HFpEF, using MRI measures before and after treatment.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | University of Florida Academic / other |
| Locations | 1 site (Gainesville, Florida) |
| Status | Recruiting |
| Started | November 3, 2023 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2027 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT07634640 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with HFpEF who do not have renal insufficiency are eligible.
✕Probably not a fit
Patients with renal insufficiency or contraindications to gadolinium or ferumoxytol may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase interventional study enrolls adults with heart failure with preserved ejection fraction and no renal insufficiency. Participants receive a gadolinium-enhanced cardiac MRI, followed by an iron infusion with ferumoxytol, and then a repeat MRI 72 hours later to assess changes in imaging markers. The study is conducted at the University of Florida with collaboration from the American Heart Association. Outcomes focus on imaging-derived indicators of inflammation and iron-related effects on the heart. The sponsor is the University of Florida, with the AHA as a collaborator.
Why it matters
Potential benefit: If successful, the approach could improve understanding of inflammatory processes in HFpEF and guide future therapies.
How similar studies have gone: Prior similar studies have explored iron-based MRI markers in cardiovascular disease, but this exact intervention in HFpEF is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * HFpEF Exclusion Criteria: * Renal insufficiency
Where it's running
-
University of Florida
Gainesville, Florida, United States Recruiting
Study contacts
- Principal investigator: Ellen C Keeley, MD, MS — University of Florida
- Study coordinator: Ellen C Keeley, MD, MS
- Email: ellen.keeley@medicine.ufl.edu
- Phone: 800-265-0820
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease
This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
Resmetirom for MASH with HFpEF in adults
This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.
-
Elecoglipron vs placebo for adults with HFpEF or HFmrEF
This Phase 3 study tests whether elecoglipron helps people with HFpEF or HFmrEF who are on dapagliflozin and standard care.
-
Coronary stents for people with HFpEF and blocked heart arteries
This trial will see if placing coronary artery stents (versus a placebo procedure) helps people with HFpEF and coronary artery disease feel better over six months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.